Hidekazu Hirano

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato et al. · BMJ · 2024 · 195 citations · Full text

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

Ken Masuda, Hirokazu Shoji, Kengo Nagashima et al. · BMC Cancer · 2019 · 137 citations · Full text

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

Masahiko Aoki, Hirokazu Shoji, Kengo Nagashima et al. · ESMO Open · 2019 · 46 citations · Full text

Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens

Yuichi Abe, Hidekazu Hirano, Hirokazu Shoji et al. · Theranostics · 2020 · 30 citations · Full text

Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis

Masashi Ishikawa, Satoru Iwasa, Kengo Nagashima et al. · Investigational New Drugs · 2019 · 27 citations

Second-line Treatment, Surgical Oncology, Retrospective Comparison +7